Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors

OBJECTIVE: ABI-007 is a novel Cremophor(®) EL-free nanoparticle albumin-bound paclitaxel. This Phase I study was designed to evaluate tolerability and determine recommended dose for Japanese patients when ABI-007 was administered in every-3-week schedule. Pharmacokinetics of paclitaxel was also asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Kazuhiko, Yamamoto, Noboru, Yamada, Yasuhide, Mukohara, Toru, Minami, Hironobu, Tamura, Tomohide
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862657/
https://www.ncbi.nlm.nih.gov/pubmed/20133335
http://dx.doi.org/10.1093/jjco/hyp192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862657/
https://www.ncbi.nlm.nih.gov/pubmed/20133335
http://dx.doi.org/10.1093/jjco/hyp192

Ejemplares similares